Bioluminescence Ventures Reveals Partners and Investment Management Team
Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines, today revealed its initial team of Partners, whose collective experience and expertise spans preclinical research, translational science, clinical development, medical affairs, regulatory, commercial strategy, business development, and strategic investment banking functions across therapeutic areas.
- Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines, today revealed its initial team of Partners, whose collective experience and expertise spans preclinical research, translational science, clinical development, medical affairs, regulatory, commercial strategy, business development, and strategic investment banking functions across therapeutic areas.
- Every day, I feel honored and lucky to be working with such talented, mission-driven, and caring people.”
Chloe Kim, Ph.D. joined Bioluminescence Ventures as a Partner in 2022. - Negin Mokhtari, Ph.D. joined Bioluminescence Ventures as a Partner in 2023 and brings a blend of scientific expertise, operational experience, and investment skills to the firm.
- Prior to joining Bioluminescence Ventures, Dr. Mokhtari was part of the investment team at Genoa Ventures, focusing on the convergence of biology and technology, and serving on the board of multiple companies.